Affiliation:
1. Pirogov Russian National Research Medical University Moscow
Abstract
Today, despite the introduction of primary and secondary prevention methods, chronic non-communicable diseases remain the main cause of high morbidity and mortality throughout the world. According to some studies, hepatic component metabolic syndrome and one of the main factors contributing to the development of cardiometabolic diseases is non-alcoholic severe liver disease. According to the results of studies, NAFLD is currently the leading cause of chronic liver diseases worldwide and is closely associated with the development of cardiometabolic pathology, in particular type 2 diabetes and CVD. This review is devoted to the epidemiology, pathophysiology of the close relationship between NAFLD and type 2 diabetes, as well as therapy affecting insulin resistance, a key link connecting these two nosologies.
Reference40 articles.
1. Roglic, Gojka. WHO Global report on diabetes: A summary. International Journal of Noncommunicable Diseases 1(1): p 3–8, Apr–Jun 2016. | DOI: 10.4103/2468-8827.184853.
2. Algoritmy spetsializirovannoi meditsinskoi pomoshchi bol'nym sakharnym diabetom / Pod redaktsiei I. I. Dedova, M. V. Shestakovoi, A. Yu. Maiorova. – 11-i vypusk. – M.; 2023. doi: https://doi.org/10.14341/DM13042.
3. International Diabetes Federation. IDF Diabetes Atlas. Ninth edition. 2019. URL: https://www.diabetesatlas.org/upload/resources/2019/IDF_Atlas_9th_Edition_2019.pdf (data obrashcheniya – 15.01.2020).
4. Bhat A, Sebastiani G, Bhat M. Systematic review: preventive and therapeutic applications of metformin in liver disease. World J Hepatol. (2015) 7:1652–9. 10.4254/wjh.v7.i12.1652.
5. Portillo-Sanchez P, Bril F, Maximos M, Lomonaco R, Biernacki D, Orsak B, Subbarayan S, Webb A, Hecht J, Cusi K. High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. J Clin Endocrinol Metab 2015; 100:2231–2238.